Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea

Allergan

Status: Completed

Conditions: Glabellar Lines; Hyperhidrosis; Muscle Spasticity

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02043145

EPI-MULT-100

Details and patient eligibility

About

This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines in clinical practice.

Enrollment: 727 patients

Sex

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines.

Exclusion criteria

• None.

Trial design

727 participants in 3 patient groups

Axillary Hyperhidrosis

Description:

Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A

Focal Spasticity

Description:

Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A

Glabellar Lines

Description:

Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A